Publish Your Article


Third dose of coronavirus vaccine provides 2.5 times more protection against Omicron

The third dose of Covid-19 vaccine increases the level of antibodies that can effectively neutralize the Omicron variant of the coronavirus, according to a new study published in The Lancet.

Researchers from the Francis Crick Institute and the National Institute of Health Research (NIHR) in England found that antibodies produced in people who received only two doses of the AstraZeneca or Pfizer/BioNTech vaccine were less able to neutralize Omicron compared to the Alpha and Delta variants.

However, the scientists found that antibody levels dropped in the first three months after the second dose, but a third “booster” dose raised the levels of antibodies that effectively neutralized the Omicron variant.


However, in the study, people who received the Pfizer/BioNTech vaccine for all three doses had overall antibody levels about 2.5 times higher to Omicron compared to those who received two doses of the vaccine.

According to the news in NTV, higher levels of antibodies to Omicron were also found in people who received two doses of both vaccines and reported that they had Covid-19 symptoms before, compared to those who did not have symptoms of the disease in the past.

On the other hand, the researchers noted that while antibody levels alone do not predict the effectiveness of the vaccine, they are a very good indicator of protection against severe Covid-19. The study confirmed that three doses of Covid-19 vaccine are needed to raise antibodies to measurable levels and maximize the amount of protection against serious illness and hospitalizations.

Emma Wall, infectious diseases consultant at the NIHR’s UCLH Center for Biomedical Research, “People lining up outside of vaccination centers should be reassured that the best way to protect themselves from Omicron is with a vaccine booster. It’s not too late for people who haven’t had a third dose or even their first dose of vaccine yet.” said.

On the other hand, the researchers analyzed 620 blood samples from 364 people who participated in the study.

Antibodies against different variants of the corona virus, including Omicron “neutralizing antibodies” They tested the ability of the so-called virus to block entry into cells.


The researchers also included synthetic neutralizing antibodies currently used for Covid-19 therapy to test whether they have neutralizing activity against coronavirus variants.

The team found that Xevudy (sotrovimab), a recently approved synthetic monoclonal antibody used to prevent and treat patients at risk of developing severe Covid-19, was able to neutralize the Omicron variant.

Bryan Williams, Director of Research at UCLH, “We have some really important early data showing that at least some versions of the synthetic antibodies we currently use to treat certain patients may be effective against this new variant.” he said.

David LV Bauer of the Francis Crick Institute said that while Omicron has significantly more mutations than other newer variants, such as Alpha and Delta, the study shows that the boosters force the immune system into a broad response that can combat it.

Wall, “This new variant can overcome the immune blocking administered with two doses of vaccine, but after the third dose, its neutralizing activity is robust in the vast majority of people. A third dose raises your immune defenses, making it harder for the virus to cause severe Covid-19.” said.

Source: Cumhuriyet

Related posts

Fundraising campaign to buy Bayraktar from Ukraine in Lithuania: 3 million euros raised in 3 days


Zelensky calls for Russia to be recognized as a "terrorist state": "Terror, Russia's only form of action against Ukraine and Europe"


Tokyo Tower: sushi on order


The Buffalo Terrorist and the Global Anchorage of Racism

Leave a Reply

Your email address will not be published.